Catalyst Wire Dossier Catalyst Wire Dossier

INC280 (cMET inhibitor)

savolitinib · Novartis Pharmaceuticals
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for INC280 (cMET inhibitor), covering 2024-03-20 to 2024-03-20. Get the full timeline:

Most recent: Clinical Trial Update: Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) [Phase 2]

See pricing